Find, compare & contact
Acetarsol
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Acetarsol API 97-44-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Acetarsol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Acetarsol
- Synonyms:
- Cas Number:
- 97-44-9
- DrugBank number:
- DB13268
- Unique Ingredient Identifier:
- 806529YU1N
General Description:
Acetarsol, identified by CAS number 97-44-9, is a notable compound with significant therapeutic applications. Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. It has been canceled and withdrawn from the market since August 12, 1997.
Indications:
This drug is primarily indicated for: Acetarsol has been used for the treatment of different diseases such as syphilis, amoebiasis, yaws, trypanosomiasis, and malaria. Acetarsol was used commonly for the treatment of vaginitis due to _Trichomonas vaginalis_ and _Candida albicans_. When orally administered, acetarsol can be used for the treatment of intestinal amoebiasis and in the form of suppositories it has been researched for the treatment of proctitis. Protozoan infections are parasitic diseases characterized to be caused by organisms classified in the kingdom Protozoa which is formed by a great diversity of organisms. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Acetarsol undergoes metabolic processing primarily in: This pharmacokinetic property was not addressed. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Acetarsol are crucial for its therapeutic efficacy: The absorption seems to be very minimal but there are reports of allergic reactions after vaginal administration of acetarsol. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Acetarsol is an important consideration for its dosing schedule: This pharmacokinetic property was not addressed. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Acetarsol exhibits a strong affinity for binding with plasma proteins: This pharmacokinetic property was not addressed. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Acetarsol from the body primarily occurs through: The arsenic found in acetarsol is excreted mainly in the urine. The level of arsenic after acetarsol administration almost reaches the toxic range in urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Acetarsol is distributed throughout the body with a volume of distribution of: This pharmacokinetic property was not addressed. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Acetarsol is a critical factor in determining its safe and effective dosage: This pharmacokinetic property was not addressed. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Acetarsol exerts its therapeutic effects through: Some reports indicate a certain infection remission with the use of acetarsol but this reports also demonstrate the absorption of systemic arsenic which can be physiologically dangerous. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Acetarsol functions by: The mechanism of action of acetarsol is not well known but it is thought to bind to protein-containing sulfhydryl groups located in the infective microorganism and to form a lethal As-S bond. The formation of this bond impairs the protein to function and it eventually kills the microorganism. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Acetarsol belongs to the class of organic compounds known as acetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group, classified under the direct parent group Acetanilides. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Anilides subclass.
Categories:
Acetarsol is categorized under the following therapeutic classes: Agents Against Leishmaniasis and Trypanosomiasis, Alimentary Tract and Metabolism, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Arsenicals, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Intestinal Antiinfectives. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Acetarsol include:
- Water Solubility: Slightly soluble
- Melting Point: 225-227 ºC
Acetarsol is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.